Over the past 12 months, 10 insiders at Arcutis Biotherapeutics, Inc. filed 83 open-market SEC Form 4 transactions on ARQT: 0 purchases worth $0 and 83 sales worth $16.4M. Insiders have been net sellers over this period. The most recent filing was on Jul 15, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 26 | Howard G. WelgusDirector | SELL | 4.7K | $26.91 | $127K |
| Jun 17, 26 | Howard G. Welgus | SELL | 635 | $25.67 | $16K |
| Jun 15, 26 | Sue-jean Lin | SELL | 4.9K | $24.38 | $121K |
| Jun 15, 26 | Howard G. Welgus | SELL | 4.1K | $24.41 | $100K |
| May 11, 26 | Patrick BurnettSee Remarks | SELL | 222 | $21.05 | $5K |
| May 11, 26 | Latha VairavanSVP Chief Financial Officer | SELL | 435 | $21.05 | $9K |
| May 4, 26 | Patrick BurnettSee Remarks | SELL | 684 | $23.61 | $16K |
| May 4, 26 | Masaru MatsudaSee Remarks | SELL | 7.4K | $23.61 | $172K |
| May 4, 26 | Latha VairavanSVP Chief Financial Officer | SELL | 1.3K | $23.61 | $32K |
| May 4, 26 | Todd WatanabeSee Remarks | SELL | 3.2K | $23.61 | $75K |
| May 1, 26 | Howard G. Welgus | SELL | 7.1K | $22.99 | $164K |
| Mar 2, 26 | Keith R LeonardDirector | SELL | 39.3K | $25.39 | $997K |
| Mar 2, 26 | Howard G. WelgusDirector | SELL | 10.0K | $25.65 | $257K |
| Mar 2, 26 | Larry Todd EdwardsSee Remarks | SELL | 3.6K | $25.91 | $90K |
| Mar 2, 26 | Masaru MatsudaSee Remarks | SELL | 6.6K | $25.91 | $165K |
| Mar 2, 26 | Latha VairavanSVP Chief Financial Officer | SELL | 2.8K | $25.91 | $70K |
| Mar 2, 26 | Todd WatanabeSee Remarks | SELL | 36.3K | $25.91 | $913K |
| Mar 2, 26 | Patrick BurnettSee Remarks | SELL | 6.1K | $25.91 | $154K |
| Feb 27, 26 | Masaru MatsudaSee Remarks | SELL | 3.3K | $27.95 | $93K |
| Feb 4, 26 | Patrick BurnettSee Remarks | SELL | 9.8K | $25.81 | $253K |
| Feb 2, 26 | Patrick BurnettSee Remarks | SELL | 3.7K | $25.50 | $94K |
| Feb 2, 26 | Larry Todd EdwardsSee Remarks | SELL | 2.1K | $25.50 | $52K |
| Feb 2, 26 | Masaru MatsudaSee Remarks | SELL | 19.4K | $25.63 | $489K |
| Feb 2, 26 | Latha VairavanSVP Chief Financial Officer | SELL | 1.3K | $25.50 | $34K |
| Feb 2, 26 | Todd WatanabeSee Remarks | SELL | 19.8K | $25.50 | $506K |
| Feb 2, 26 | Howard G. WelgusDirector | SELL | 10.0K | $25.05 | $251K |
| Jan 5, 26 | Patrick BurnettSee Remarks | SELL | 2.5K | $28.98 | $72K |
| Jan 2, 26 | Howard G. WelgusDirector | SELL | 10.0K | $28.96 | $290K |
| Dec 31, 25 | Patrick BurnettSee Remarks | SELL | 1.2K | $29.39 | $34K |
| Dec 15, 25 | Patrick BurnettSee Remarks | SELL | 11.5K | $28.94 | $333K |
| Dec 1, 25 | Masaru MatsudaSee Remarks | SELL | 1.7K | $30.23 | $50K |
| Dec 1, 25 | Howard G. WelgusDirector | SELL | 10.0K | $30.21 | $302K |
| Nov 24, 25 | Sue-jean LinDirector | SELL | 25.3K | $30.78 | $778K |
| Nov 24, 25 | Todd WatanabeSee Remarks | SELL | 48.9K | $30.36 | $1.5M |
| Nov 21, 25 | Todd WatanabeSee Remarks | SELL | 1.1K | $30.00 | $32K |
| Nov 20, 25 | Halley E GilbertDirector | SELL | 16.5K | $27.55 | $455K |
| Nov 19, 25 | Masaru MatsudaSee Remarks | SELL | 1.6K | $28.50 | $44K |
| Nov 13, 25 | Neha KrishnamohanDirector | SELL | 39.3K | $23.37 | $911K |
| Nov 6, 25 | Patrick BurnettSee Remarks | SELL | 17.3K | $24.18 | $417K |
| Nov 6, 25 | Larry Todd EdwardsSee Remarks | SELL | 29.1K | $25.16 | $733K |
| Nov 5, 25 | Patrick BurnettSee Remarks | SELL | 3.9K | $23.72 | $92K |
| Nov 3, 25 | Patrick BurnettSee Remarks | SELL | 2.6K | $25.40 | $64K |
| Nov 3, 25 | Masaru MatsudaSee Remarks | SELL | 7.2K | $25.40 | $177K |
| Nov 3, 25 | Latha VairavanSVP Chief Financial Officer | SELL | 88 | $24.72 | $2K |
| Nov 3, 25 | Todd WatanabeSee Remarks | SELL | 11.5K | $25.40 | $284K |
| Nov 3, 25 | Howard G. WelgusDirector | SELL | 10.0K | $25.27 | $253K |
| Oct 28, 25 | Todd WatanabeSee Remarks | SELL | 40.0K | $25.03 | $1.0M |
| Oct 2, 25 | Larry Todd EdwardsSee Remarks | SELL | 4.2K | $20.78 | $84K |
| Oct 2, 25 | Todd WatanabeSee Remarks | SELL | 20.7K | $20.04 | $416K |
| Oct 1, 25 | Todd WatanabeSee Remarks | SELL | 15.0K | $20.02 | $284K |
Over the past 12 months, insiders at Arcutis Biotherapeutics, Inc. filed 0 open-market purchases worth $0 and 83 sales worth $16.4M on ARQT, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 15, 26.
10 different insiders at Arcutis Biotherapeutics, Inc. filed open-market SEC Form 4 transactions on ARQT over the last 12 months.
InsiderTape plots every ARQT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Arcutis Biotherapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →